| Original language | English (US) |
|---|---|
| Pages (from-to) | 1871-1875 |
| Number of pages | 5 |
| Journal | Movement Disorders |
| Volume | 33 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2018 |
| Externally published | Yes |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Targeting the pedunculopontine nucleus in Parkinson's disease : Time to go back to the drawing board. / Albin, Roger L.; Surmeier, D. James; Tubert, Cecilia; Sarter, Martin; Müller, Martijn L.T.M.; Bohnen, Nicolaas I.; Dauer, William T.
In: Movement Disorders, Vol. 33, No. 12, 12.2018, p. 1871-1875.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Targeting the pedunculopontine nucleus in Parkinson's disease
T2 - Time to go back to the drawing board
AU - Albin, Roger L.
AU - Surmeier, D. James
AU - Tubert, Cecilia
AU - Sarter, Martin
AU - Müller, Martijn L.T.M.
AU - Bohnen, Nicolaas I.
AU - Dauer, William T.
N1 - Funding Information: R.L.A. receives compensation of Data Safety and Monitoring Board service for the LEGATO-HD (Teva/ICON), HTTRX (Ionis), and PASSPORT (Biogen/ICON) trials. He receives grant support from R25 NS089450, R21 NS088302, P50 1P50NS091856, P30 1P30AG053760, and the Michael J. Fox Foundation. D.J.S. received compensation for consulting services Adamas Pharmaceuticals and Pfizer, Inc. He has grant support from NIH, Cure Huntington Disease Initiative, Michael J. Fox Foundation, JPB Foundation, Bumpus Foundation, Innovation, Development, Progress Foundation Foundation, National Parkinson Foundation, Adamas Pharmaceuticals, and John Flanagan. C.T. has nothing to disclose. M.S. received compensation for consulting services for Takeda Pharmaceuticals Inc. and Pfizer Inc. He receives grant support from H. Lundbeck (Denmark), Takeda Pharmaceuticals Inc., and Public Health Service Grants P50NS091856 and PO1 DA031656. N.I.B. receives grant support from the NIH, Michael J. Fox Foundation, the Department of Veteran Affairs, Chase Pharmaceuticals, and Axovant Sciences. M.L.T.M.M. receives grant support from P50NS091856 and the Michael J. Fox Foundation. W.T.D. receives grant support from P50NS091856, R01NS077730, Tyler's Hope for a Dystonia Cure Foundation, and the Michael J. Fox Foundation. Funding Information: *Corresponding author: Dr. Roger L. Albin, 5023 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI, 48109-2200; ralbin@umich.edu Funding agencies: Supported by P50 NS091856, R21 NS088302, and the Michael J. Fox Foundation.
PY - 2018/12
Y1 - 2018/12
UR - http://www.scopus.com/inward/record.url?scp=85056201576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056201576&partnerID=8YFLogxK
U2 - 10.1002/mds.27540
DO - 10.1002/mds.27540
M3 - Article
C2 - 30398673
AN - SCOPUS:85056201576
VL - 33
SP - 1871
EP - 1875
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 12
ER -